Pacritinib for relapsed or refractory T‑cell lymphoma
Pacritinib in rel/refr T-cell lymphomas
This project will see if the drug pacritinib can help people whose T‑cell lymphoma has returned or not responded to prior treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11141119 on NIH RePORTER |
What this research studies
If you join, you would receive pacritinib, an oral drug that blocks signaling pathways used by malignant T cells and the tumor‑associated immune cells that help them. Doctors will track tumor size, side effects, and changes in immune cells from blood or tumor samples. The study combines laboratory tests on samples with clinical monitoring to understand how the drug works and who might benefit. Visits and tests will likely take place at the University of Michigan medical center.
Who could benefit from this research
Good fit: Adults with relapsed or refractory T‑cell lymphoma who have progressed after standard therapies and meet the study's health and safety criteria would be the best fit.
Not a fit: People with newly diagnosed T‑cell lymphoma, other cancer types, or serious uncontrolled medical conditions may not be eligible or likely to benefit from this trial.
Why it matters
Potential benefit: If successful, this approach could shrink tumors, extend remissions, or provide a new option for people with relapsed or refractory T‑cell lymphoma.
How similar studies have performed: Prior early‑phase trials of kinase inhibitors in T‑cell lymphoma have produced some partial responses but rarely durable remissions, and targeting tumor‑associated macrophages is a newer strategy with limited prior success.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Wilcox, Ryan a — University of Michigan at Ann Arbor
- Study coordinator: Wilcox, Ryan a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.